ACI Submits Response On Behalf of our Members to ACMD’s Call for Evidence on Cannabinoids in CBD Products
Following a consultation with our members ACI have compiled a response to the Advisory Council on the Misuse of Drugs’ (ACMD) recent call for evidence on cannabinoids in CBD products.
[Jersey Hemp] ‘Good Science is the Route To a Safer And More Successful Cbd Industry’
As Novel Food regulations for CBD products come into effect, Jersey Hemp speaks to ACI’s External Affairs director Shomi Malik about the importance of robust, relevant scientific data in moving the industry into the mainstream.
28-30 April: VOXPO – CBD Live
Voxpo is Europe’s biggest dedicated virtual CBD and medical cannabis expo. ACI will have a stand at the event and are education partner.
[CBD Bible] The ACI Strongly Refute Contents of Letter Published by BHA, CTA, NIHA and SHA
The Association for the Cannabinoid Industry (ACI) has publicly refuted the content and claims made in a letter published and shared widely on social media on Friday 26 March 2021.
New and Emerging Novel Foods, Westminster Food & Nutrition Forum
The UK regulatory system, market development, safety, and innovation in the food sector ACI Regulatory and Compliance Associate Dr Parveen Bhatarah spoke at this conference on the 27th April 2021, hosted by Westminster Food & Nutrition Forum, focusing on the regulation of new and emerging novel foods in the UK – including the way forward […]
ACMD Consumer CBD Products: call for evidence
ACMD has been commissioned to provide impartial and independent scientific advice on the acceptable levels of constituent cannabinoids in CBD products marketed as consumer products. In this member event ACI will gather input from our members for our response.
ACI Strongly Refute Contents of Letter Published by BHA, CTA, NIHA and SHA
ACI today publicly rebuts the content and claims made in a letter published and shared widely on social media on Friday 26 March 2021.
Update on Development of FSA’s Public List
On Friday 26 March 2021, ACI representatives met with the FSA for clarification relating to the novel foods validation process and the publication of the list that they mentioned in their update on 12 March.
aci-and-cmc-recommend-home-office-allows-0-03-thc-limit-for-cbd-products
[BusinessCann] Human Trial Showing CBD Safe A Boost For Industry In Battles With Regulators
Results from a major US trial over 800 people over the past seven months found CBD use has zero impact on the liver. ACI member, Columbia Care, Charlotte’s Web and 10 other US companies provided around $1m for a trial which started last summer – and now appears to have answered the CBD safety question.
